Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic ...

Leerink Partners analyst Daniel Clark reiterated a Buy rating on Zoetis (ZTS – Research Report) on January 13 and set a price target of $215.00. Discover outperforming stocks and invest smarter ...

Parsippany, New Jersey-based Zoetis Inc. (ZTS) discovers, develops, and commercializes animal health medicines, vaccines, and diagnostic products and services. With a market cap of $75.4 billion ...

Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. Wall Street Rallies On Election Day, Palantir Skyrockets, Bitcoin Tops $70,000: What's Driving Markets Tuesday? Wall Street rallied ...

Shares of Zoetis (NYSE:ZTS) traded lower on Tuesday after the U.S. FDA notified veterinarians about adverse events linked to the company’s pain therapy, Librela (bedinvetmab injection ...

In a report released yesterday, Daniel Clark from Leerink Partners maintained a Buy rating on Zoetis (ZTS – Research Report), with a price target of $205.00. Discover outperforming stocks and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...